We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

54 hedge funds and large institutions have $4.75M invested in Navidea Biopharmaceuticals Inc. in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

0% more funds holding

Funds holding: 54 → 54 (0)

4% less capital invested

Capital invested by funds: $4.93M → $4.75M (-$180K)

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

Holders
54
Holders Change
–
Holders Change %
0%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
13
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$23.3K
2
Citigroup
Citigroup
New York
+$14.9K
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$14.5K
4
PP
PDS Planning
Ohio
+$13.4K
5
USAA
United Services Automobile Association
Texas
+$9.83K

Top Sellers

Rank Fund Capital Flow
1
SFS
Sowell Financial Services
Arkansas
-$76K
2
UBS Group
UBS Group
Switzerland
-$33.1K
3
Jane Street
Jane Street
New York
-$24.6K
4
HighTower Advisors
HighTower Advisors
Illinois
-$23.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$10.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$15K +$14.9K +1,990 +3,980%
Bank of America
27
Bank of America
North Carolina
$13K – – –
PP
28
PDS Planning
Ohio
$13K +$13.4K +1,798 New
Jane Street
29
Jane Street
New York
$11K -$24.6K -3,291 -69%
Commonwealth Equity Services
30
Commonwealth Equity Services
Massachusetts
$11K +$75 +10 +0.7%
LFG
31
LifePlan Financial Group
Ohio
$10K – – –
USAA
32
United Services Automobile Association
Texas
$9K +$9.83K +1,315 New
JCM
33
Jacobi Capital Management
Pennsylvania
$7K – – –
LA
34
Lynch & Associates
Indiana
$6K – – –
MCG
35
McCollum Christoferson Group
New York
$6K – – –
RJA
36
Raymond James & Associates
Florida
$6K – – –
Ameriprise
37
Ameriprise
Minnesota
$5K – – –
MML Investors Services
38
MML Investors Services
Massachusetts
$5K +$935 +125 +22%
TRCT
39
Tower Research Capital (TRC)
New York
$5K +$3.69K +493 +196%
PNC Financial Services Group
40
PNC Financial Services Group
Pennsylvania
$5K +$5.61K +750 New
VF
41
Virtu Financial
New York
$4K -$2K -267 -33%
B
42
Bailard
California
$4K – – –
CIBC World Market
43
CIBC World Market
Ontario, Canada
$4K – – –
HC
44
Hamilton Capital
Ohio
$4K – – –
ASN
45
Advisory Services Network
Georgia
$2K -$97 -13 -5%
AWM
46
Aevitas Wealth Management
Massachusetts
$2K – – –
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$1K -$1.53K -205 -61%
AG
48
Advisor Group
Arizona
$1K -$561 -75 -43%
CPIG
49
Chicago Partners Investment Group
Illinois
$1K – – –
MFW
50
Mosaic Family Wealth
Missouri
$1K – – –
1
2
3

NAVB Hedge Fund Activity: Q1 2018 in Review

54 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2018, worth a combined $4.75M — down 3.7% from $4.93M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NAVB positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 13 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $23.3K. The largest seller was Sowell Financial Services, cutting an estimated $76K.

  • 54 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $4.75M of Navidea Biopharmaceuticals Inc. stock for Q1 2018, down 3.7% quarter-over-quarter.
  • 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2018 and 3 closed out, a net change of +1 holder.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $23.3K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2018 was Sowell Financial Services, an estimated $76K sold.

Based on aggregated 13F filings for Q1 2018.